Impel NeuroPharma Announces FDA Clearance of IND for Pivotal Phase 3 Study of INP104 for Acute Treatment of Migraine
SEATTLE, June 22, 2018 -- (Healthcare Sales & Marketing Network) -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Fo... Biopharmaceuticals, Drug Delivery, Neurology, FDA Impel NeuroPharma, Precision Olfactory Delivery, migraine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Brain | Headache | Marketing | Migraine | Neurology | Pharmaceuticals | Study